Indeed, the TNBC survival rate remains the lowest with respect to those of other BC subtypes: targeted hormonal therapies are almost ineffective, since TNBC cells lack estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2) [33,34]. The gene discussed is ERBB2; the disease is breast cancer.